EUVIMEDEUVIMED entdecken
Crossref

Evaluating eribulin's ability to produce a cytokine immune response in lung cancer

Wyatt Hinkle, Hinz, Trista K., Gurulé, Natalia J., Lynn E. Heasley

Mines Repository · 05.12.2023

DOI: 10.25676/11124/178590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mines Repository, erschienen am 05.12.2023. Verfasst von Wyatt Hinkle und 5 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to examine the ability of Eribulin, a non-taxane microtubule inhibitor, to induce a cytokine immune response similar to that of targeted TKI's in lung cancer cell lines, and furthermore to characterize the cytokine response to general growth arrest therapies compared to specific targeted protein kinase inhibitors such as TKI's.

Schlagwörter

eribulinlung cancermicrotubule inhibitorstyrosine kinase inhibitorstargeted therapygrowth arrestcancer cell linesimmunotherapy

Zitieren

APA

Hinkle, W., Hinz, K., T., Gurulé, J., N., & Heasley, L. E. (2023). Evaluating eribulin's ability to produce a cytokine immune response in lung cancer. Mines Repository. https://doi.org/10.25676/11124/178590

Vancouver

Hinkle W, Hinz, K. T, Gurulé, J. N, Heasley LE. Evaluating eribulin's ability to produce a cytokine immune response in lung cancer. Mines Repository. 2023. doi:10.25676/11124/178590

BibTeX
@article{Hinkle2023,
  author = {Hinkle, Wyatt and Hinz and K., Trista and Gurulé and J., Natalia and Heasley, Lynn E.},
  title = {Evaluating eribulin's ability to produce a cytokine immune response in lung cancer},
  journal = {Mines Repository},
  year = {2023},
  doi = {10.25676/11124/178590}
}
Kostenlos starten →